<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00092976</url>
  </required_header>
  <id_info>
    <org_study_id>3082A2-401</org_study_id>
    <nct_id>NCT00092976</nct_id>
  </id_info>
  <brief_title>Study Evaluating ReFacto® in Hemophilia A Undergoing Major Surgery</brief_title>
  <official_title>A Phase IV Study of the Safety and Efficacy of ReFacto® (Moroctocog Alfa, B-Domain Deleted Recombinant Factor VIII) in Subjects With Hemophilia A Undergoing Major Surgery Monitored Using the Chromogenic Substrate Assay at the Local Laboratory</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <brief_summary>
    <textblock>
      The primary objective of this clinical research study is to evaluate the safety and efficacy
      of ReFacto in subjects with hemophilia A undergoing major surgery monitored using the
      chromogenic substrate assay at the local laboratory.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and efficacy of ReFacto in subjects with Hemophilia A undergoing major surgery monitored using the chromogenic substrate assay at the local laboratory.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare FVIII:C levels determined using the one-stage and the chromogenic substrate assays at a central laboratory</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Hemophilia A</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ReFacto</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 6 years

          -  Male previously treated patients (≥150 Exposure Days) with moderate or severe
             hemophilia A (i.e. ≤ 5% FVIII:C) who will undergo elective major surgery that is
             anticipated to require at least 6 consecutive days of daily factor VIII (FVIII)
             infusions (surgical and post-surgical prophylaxis)

          -  Ability to adhere to the protocol requirements

        Exclusion Criteria:

          -  Hypersensitivity to ReFacto, murine allergen, or hamster allergen 2 History of FVIII
             inhibitor or current inhibitor, defined as &gt; 0.6 BU

          -  Prior participation in this study

          -  Any concomitant bleeding disorder other than hemophilia A
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor, MD</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903-0019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2004</study_first_submitted>
  <study_first_submitted_qc>September 28, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2004</study_first_posted>
  <last_update_submitted>December 19, 2007</last_update_submitted>
  <last_update_submitted_qc>December 19, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 28, 2007</last_update_posted>
  <keyword>Hemophilia A</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

